Search results for "Therapeutic apheresis"

showing 3 items of 3 documents

MOLECULAR AND CELLULAR APPROACHES IN TRANSFUSION MEDICINE

Settore MED/04 - Patologia GeneraleTansfusion medicine Therapeutic Apheresis Regenerative Medicine Stem cells Blood groups molecular biology
researchProduct

Update to the ASFA guidelines on the use of therapeutic apheresis in ANCA‐associated vasculitis

2020

Since 1986, the American Society for Apheresis (ASFA) has published practice guidelines on the use of therapeutic apheresis in the Journal of Clinical Apheresis (JCA) Special Issue. Since 2007, updated guidelines have been published every 3 years to reflect current evidence based apheresis practice with the most recent edition (8th) published in 2019. With each edition, the guidelines are reviewed and updated based on any newly published literature since the last review. The PEXIVAS study, an international, randomized controlled trial comparing therapeutic plasma exchange (TPE) vs no TPE and standard vs reduced dose steroid regimen on the primary composite outcome of end stage renal disease…

medicine.medical_specialtyEvidence-based practiceAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisANCA-Associated Vasculitis030204 cardiovascular system & hematologyEnd stage renal diseaselaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawmedicineHumansIntensive care medicineSocieties MedicalTherapeutic apheresisPlasma Exchangebusiness.industryHematologyGeneral Medicinemedicine.diseaseRegimenApheresisPractice Guidelines as TopicBlood Component RemovalbusinessVasculitis030215 immunologyJournal of Clinical Apheresis
researchProduct

RheoNet Registry Analysis of Rheopheresis for Microcirculatory Disorders With a Focus on Age-Related Macular Degeneration

2010

The purpose of establishing the RheoNet registry was to evaluate the safety and efficacy of rheopheresis, a specific method of therapeutic apheresis used to treat microcirculatory disorders. Apheresis centers providing rheopheresis therapy and physicians caring for the underlying disease were asked to participate in the registry, and the registry data were analyzed for safety and tolerability. Age-related macular degeneration (AMD) was selected as a model disease to evaluate efficacy. The RheoNet registry was successfully established recording 7722 rheopheresis treatments of 1110 patients, including 833 AMD patients. The mean age of patients was 72 years. Adverse events (AE) were reported i…

medicine.medical_specialtyVisual acuitygenetic structuresbusiness.industryRheopheresisHematologyMacular degenerationmedicine.diseaseeye diseasesSurgeryApheresisTolerabilityNephrologyAge relatedInternal medicinemedicinemedicine.symptomAdverse effectbusinessTherapeutic apheresisTherapeutic Apheresis and Dialysis
researchProduct